;PMID: 9603197
;source_file_2857.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:43..207] = [t:43..207]
;2)section:[e:211..273] = [t:211..273]
;3)section:[e:277..349] = [t:277..349]
;4)sentence:[e:353..606] = [t:353..606]
;5)sentence:[e:607..740] = [t:607..740]
;6)sentence:[e:742..878] = [t:742..878]
;7)sentence:[e:879..1117] = [t:879..1117]
;8)sentence:[e:1118..1314] = [t:1118..1314]
;9)section:[e:1318..1362] = [t:1318..1362]

;section 0 Span:0..37
;J Neurochem.  1998 Jun;70(6):2327-35.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..11] Neurochem) (.:[11..12] .) (CD:[14..18] 1998)
        (.:[19..25] Jun;70) (-LRB-:[25..26] -LRB-) (CD:[26..27] 6)
        (-RRB-:[27..28] -RRB-) (::[28..29] :) (CD:[29..33] 2327)
        (CD:[33..36] -35) (.:[36..37] .)))

;sentence 1 Span:43..207
;Effects of a peptide analogue of the amphiphilic domain of the common 
;neurotrophin receptor on nerve growth factor-mediated motility of human 
;neuroblastoma cells.
;[114..135]:gene-protein:"neurotrophin receptor"
;[139..158]:gene-protein:"nerve growth factor"
;[187..200]:malignancy-type:"neuroblastoma"
(SENT
  (NP-HLN
    (NP (NNS:[43..50] Effects))
    (PP (IN:[51..53] of)
      (NP
        (NP (DT:[54..55] a) (NN:[56..63] peptide) (NN:[64..72] analogue))
        (PP (IN:[73..75] of)
          (NP
            (NP (DT:[76..79] the) (JJ:[80..91] amphiphilic) (NN:[92..98] domain))
            (PP (IN:[99..101] of)
              (NP (DT:[102..105] the) (JJ:[106..112] common)
                 (NN:[114..126] neurotrophin) (NN:[127..135] receptor)))))))
    (PP (IN:[136..138] on)
      (NP
        (NP
          (ADJP
             (NN:[139..144] nerve) (NN:[145..151] growth) (NN:[152..158] factor)
            (HYPH:[158..159] -) (VBN:[159..167] mediated))
          (NN:[168..176] motility))
        (PP (IN:[177..179] of)
          (NP (JJ:[180..185] human) (NN:[187..200] neuroblastoma)
              (NNS:[201..206] cells)))))
    (.:[206..207] .)))

;section 2 Span:211..273
;Wang W, Dostaler SM, Lawrence G, Ross GM, Riopelle RJ, Dow KE.
(SEC
  (FRAG (NNP:[211..215] Wang) (NNP:[216..217] W) (,:[217..218] ,)
        (NNP:[219..227] Dostaler) (NNP:[228..230] SM) (,:[230..231] ,)
        (NNP:[232..240] Lawrence) (NNP:[241..242] G) (,:[242..243] ,)
        (NNP:[244..248] Ross) (NNP:[249..251] GM) (,:[251..252] ,)
        (NNP:[253..261] Riopelle) (NNP:[262..264] RJ) (,:[264..265] ,)
        (NNP:[266..269] Dow) (NNP:[270..273] KE.)))

;section 3 Span:277..349
;Department of Pediatrics, Queen's University, Kingston, Ontario, Canada.
(SEC
  (FRAG (NNP:[277..287] Department) (IN:[288..290] of)
        (NNP:[291..301] Pediatrics) (,:[301..302] ,) (NNP:[303..308] Queen)
        (POS:[308..310] 's) (NNP:[311..321] University) (,:[321..322] ,)
        (NNP:[323..331] Kingston) (,:[331..332] ,) (NNP:[333..340] Ontario)
        (,:[340..341] ,) (NNP:[342..348] Canada) (.:[348..349] .)))

;sentence 4 Span:353..606
;Exposure of human neuroblastoma cells (IMR-32) to a peptide mimic of the 
;cytoplasmic amphiphilic domain of the common neurotrophin receptor (p75NTR 
;367-379) resulted in enhanced nerve growth factor (NGF)-mediated inhibition
;of  cell invasion in vitro.
;[371..384]:malignancy-type:"neuroblastoma"
;[472..493]:gene-protein:"neurotrophin receptor"
;[495..501]:gene-protein:"p75NTR"
;[533..552]:gene-protein:"nerve growth factor"
;[554..557]:gene-protein:"NGF"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[353..361] Exposure))
      (PP (IN:[362..364] of)
        (NP (JJ:[365..370] human) (NN:[371..384] neuroblastoma)
            (NNS:[385..390] cells)))
      (PRN (-LRB-:[391..392] -LRB-)
        (NP (NN:[392..398] IMR-32))
        (-RRB-:[398..399] -RRB-))
      (PP (TO:[400..402] to)
        (NP
          (NP (DT:[403..404] a) (NN:[405..412] peptide) (NN:[413..418] mimic))
          (PP (IN:[419..421] of)
            (NP
              (NP (DT:[422..425] the) (JJ:[427..438] cytoplasmic)
                  (JJ:[439..450] amphiphilic) (NN:[451..457] domain))
              (PP (IN:[458..460] of)
                (NP
                  (NP (DT:[461..464] the) (JJ:[465..471] common)
                     (NN:[472..484] neurotrophin) (NN:[485..493] receptor))
                  (NP (-LRB-:[494..495] -LRB-) (NN:[495..501] p75NTR)
                      (CD:[503..506] 367) (HYPH:[506..507] -)
                      (CD:[507..510] 379) (-RRB-:[510..511] -RRB-)))))))))
    (VP (VBD:[512..520] resulted)
      (PP-CLR (IN:[521..523] in)
        (NP
          (NP (VBN:[524..532] enhanced)
            (ADJP
              (NML
                (NML (NN:[533..538] nerve) (NN:[539..545] growth)
                     (NN:[546..552] factor))
                (NML (-LRB-:[553..554] -LRB-) (NN:[554..557] NGF)
                     (-RRB-:[557..558] -RRB-)))
              (HYPH:[558..559] -) (VBN:[559..567] mediated))
            (NN:[568..578] inhibition))
          (PP (IN:[579..581] of)
            (NP (NN:[583..587] cell) (NN:[588..596] invasion)))
          (ADJP (FW:[597..599] in) (FW:[600..605] vitro)))))
    (.:[605..606] .)))

;sentence 5 Span:607..740
;The peptide also enhanced NGF-mediated neurite extension  and GAP-43 gene
;expression but had no effect on NGF-mediated cell survival.
;[633..636]:gene-protein:"NGF"
;[669..675]:gene-rna:"GAP-43"
;[713..716]:gene-protein:"NGF"
(SENT
  (S
    (NP-SBJ (DT:[607..610] The) (NN:[611..618] peptide))
    (ADVP (RB:[619..623] also))
    (VP
      (VP (VBD:[624..632] enhanced)
        (NP
          (NP
            (ADJP (NN:[633..636] NGF) (HYPH:[636..637] -)
                  (VBN:[637..645] mediated))
            (NN:[646..653] neurite) (NN:[654..663] extension))
          (CC:[665..668] and)
          (NP (NN:[669..675] GAP-43) (NN:[676..680] gene)
              (NN:[681..691] expression))))
      (CC:[692..695] but)
      (VP (VBD:[696..699] had)
        (NP
          (NP (DT:[700..702] no) (NN:[703..709] effect))
          (PP (IN:[710..712] on)
            (NP
              (ADJP (NN:[713..716] NGF) (HYPH:[716..717] -)
                    (VBN:[717..725] mediated))
              (NN:[726..730] cell) (NN:[731..739] survival))))))
    (.:[739..740] .)))

;sentence 6 Span:742..878
;These latter functional effects mimicked influences on NGF-mediated neurite 
;growth in other trkA-positive cells as reported previously.
;[797..800]:gene-protein:"NGF"
;[835..839]:gene-generic:"trkA"
(SENT
  (S
    (NP-SBJ (DT:[742..747] These) (JJ:[748..754] latter)
            (JJ:[755..765] functional) (NNS:[766..773] effects))
    (VP (VBD:[774..782] mimicked)
      (NP (NNS:[783..793] influences)
        (PP (IN:[794..796] on)
          (NP
            (ADJP (NN:[797..800] NGF) (HYPH:[800..801] -)
                  (VBN:[801..809] mediated))
            (NN:[810..817] neurite) (NN:[819..825] growth))))
      (PP (IN:[826..828] in)
        (NP (JJ:[829..834] other)
          (ADJP (NN:[835..839] trkA) (HYPH:[839..840] -)
                (JJ:[840..848] positive))
          (NNS:[849..854] cells)))
      (SBAR (IN:[855..857] as)
        (S
          (NP-SBJ-1 (-NONE-:[857..857] *))
          (VP (VBN:[858..866] reported)
            (NP-1 (-NONE-:[866..866] *))
            (ADVP-TMP (RB:[867..877] previously))))))
    (.:[877..878] .)))

;sentence 7 Span:879..1117
;NGF-dependent trkA  phosphorylation was significantly enhanced by the
;presence of the peptide,  whereas high-affinity binding of 125I-NGF, both NGF
;receptors mRNA and protein  expression, and trkA dimer/monomer ratios were
;not influenced.
;[879..882]:gene-protein:"NGF"
;[893..897]:gene-generic:"trkA"
;[1013..1016]:gene-protein:"NGF"
;[1023..1036]:gene-protein:"NGF receptors"
;[1023..1036]:gene-rna:"NGF receptors"
;[1071..1075]:gene-protein:"trkA"
(SENT
  (S
    (NP-SBJ-1
      (ADJP (NN:[879..882] NGF) (HYPH:[882..883] -) (JJ:[883..892] dependent))
      (NN:[893..897] trkA) (NN:[899..914] phosphorylation))
    (VP (VBD:[915..918] was)
      (ADVP (RB:[919..932] significantly))
      (VP (VBN:[933..941] enhanced)
        (NP-1 (-NONE-:[941..941] *))
        (PP (IN:[942..944] by)
          (NP
            (NP (DT:[945..948] the) (NN:[949..957] presence))
            (PP (IN:[958..960] of)
              (NP (DT:[961..964] the) (NN:[965..972] peptide)))))
        (,:[972..973] ,)
        (SBAR-ADV (IN:[975..982] whereas)
          (S
            (NP-SBJ-4
              (NP
                (NP
                  (ADJP (JJ:[983..987] high) (HYPH:[987..988] -)
                        (NN:[988..996] affinity))
                  (NN:[997..1004] binding))
                (PP (IN:[1005..1007] of)
                  (NP
                    (NP (NN:[1008..1013] 125I-) (NN:[1013..1016] NGF))
                    (,:[1016..1017] ,)
                    (NP (CC:[1018..1022] both)
                      (NP
                         (NN:[1023..1026] NGF) (NNS:[1027..1036] receptors)
                        (NN:[1037..1041] mRNA))
                      (CC:[1042..1045] and)
                      (NP (NN:[1046..1053] protein) (NN:[1055..1065] expression)))
                    (,:[1065..1066] ,))))
              (CC:[1067..1070] and)
              (NP
                (NP
                  (NML-2 (NN:[1071..1075] trkA))
                  (NN:[1076..1081] dimer)
                  (NML-3 (-NONE-:[1081..1081] *P*)))
                (SYM:[1081..1082] /)
                (NP
                  (NML-2 (-NONE-:[1082..1082] *P*))
                  (NN:[1082..1089] monomer)
                  (NML-3 (NNS:[1090..1096] ratios)))))
            (VP (VBD:[1097..1101] were) (RB:[1102..1105] not)
              (VP (VBN:[1106..1116] influenced)
                (NP-4 (-NONE-:[1116..1116] *))))))))
    (.:[1116..1117] .)))

;sentence 8 Span:1118..1314
;The studies  suggest that ligand-mediated trkA activation has differential
;effects on cell  motility phenomena and that the amphiphilic domain of p75NTR
;has a role in this  differential signaling.
;[1160..1164]:gene-generic:"trkA"
;[1264..1270]:gene-protein:"p75NTR"
(SENT
  (S
    (NP-SBJ (DT:[1118..1121] The) (NNS:[1122..1129] studies))
    (VP (VBP:[1131..1138] suggest)
      (SBAR
        (SBAR (IN:[1139..1143] that)
          (S
            (NP-SBJ
              (ADJP (NN:[1144..1150] ligand) (HYPH:[1150..1151] -)
                    (VBN:[1151..1159] mediated))
              (NN:[1160..1164] trkA) (NN:[1165..1175] activation))
            (VP (VBZ:[1176..1179] has)
              (NP
                (NP (JJ:[1180..1192] differential) (NNS:[1193..1200] effects))
                (PP (IN:[1201..1203] on)
                  (NP (NN:[1204..1208] cell) (NN:[1210..1218] motility)
                      (NNS:[1219..1228] phenomena)))))))
        (CC:[1229..1232] and)
        (SBAR (IN:[1233..1237] that)
          (S
            (NP-SBJ
              (NP (DT:[1238..1241] the) (JJ:[1242..1253] amphiphilic)
                  (NN:[1254..1260] domain))
              (PP (IN:[1261..1263] of)
                (NP (NN:[1264..1270] p75NTR))))
            (VP (VBZ:[1271..1274] has)
              (NP (DT:[1275..1276] a) (NN:[1277..1281] role))
              (PP (IN:[1282..1284] in)
                (NP (DT:[1285..1289] this) (JJ:[1291..1303] differential)
                    (NN:[1304..1313] signaling))))))))
    (.:[1313..1314] .)))

;section 9 Span:1318..1362
;PMID: 9603197 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1318..1322] PMID) (::[1322..1323] :) (CD:[1324..1331] 9603197)
        (NN:[1332..1333] -LSB-) (NNP:[1333..1339] PubMed) (::[1340..1341] -)
        (NN:[1342..1349] indexed) (IN:[1350..1353] for)
        (NNP:[1354..1362] MEDLINE-RSB-)))
